investigated that the combination of DNA repair gene RAD51B promoter methylation RAD51Bme+ with PD-L1+ was more effective in predicting the response to ICI therapy than either marker alone in NSCLC (80). Here, CD274 is linked to non-small cell lung carcinoma.